Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.25 Analyst target: $5.75 Upside: 155.56%
Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company is headquartered in Malvern, Pennsylvania.
See the full interactive analysis & chart →Informational only — not investment advice.